In a Phase 1, first‑in‑human clinical trial, researchers have reported that a one‑time infusion of a new CRISPR‑Cas9 gene‑editing therapy was safe and led to major reductions in harmful blood fats — cutting LDL (“bad”) cholesterol by nearly 50% and triglycerides by about 55% in people with stubborn high lipid levels. This represents a potential game changer in treating people at very high risk of heart disease. :contentReference[oaicite:0]{index=0}
What the Therapy Does
The investigational therapy, called CTX310, is delivered in a single intravenous infusion and uses CRISPR‑Cas9 — a form of gene editing — to switch off a specific gene in the liver known as ANGPTL3. This gene normally helps regulate the levels of cholesterol and fats in the blood. By turning it off, the liver is better able to clear LDL cholesterol and triglycerides from circulation. :contentReference[oaicite:1]{index=1}
Results That Surprise Scientists
In the trial involving about 15 adults with difficult‑to‑treat lipid disorders, participants saw **major drops in LDL cholesterol and triglyceride levels** starting about two weeks after the infusion. At the highest doses tested, the reductions averaged around **50% for LDL and about 55% for triglycerides**. These reductions were still present at least 60 days after treatment. Importantly, **no serious safety concerns were reported during the initial follow‑up period**. :contentReference[oaicite:2]{index=2}
Why This Matters
Heart disease remains one of the leading causes of death worldwide, and high levels of LDL cholesterol and triglycerides are strong risk factors for heart attacks and strokes. Current treatments — like statins — require daily lifelong use and often don’t work well for everyone. A one‑time treatment that permanently lowers harmful lipids could **transform how cardiovascular disease is prevented and treated**. :contentReference[oaicite:3]{index=3}
Safety and Next Steps
So far, the gene‑editing therapy appears to be well tolerated in this early Phase 1 trial, with only mild side effects related to infusion in some participants. Researchers emphasize that the trial is still early, and longer‑term safety and effectiveness will need to be confirmed in larger Phase 2 and Phase 3 studies before it becomes widely available. :contentReference[oaicite:4]{index=4}
Looking Ahead
If future studies confirm these results, this CRISPR‑based therapy could offer a **“one‑and‑done” alternative** to chronic cholesterol medications, especially for people whose lipid levels remain high despite current treatments. It may also provide new hope for those with genetic forms of high cholesterol and triglycerides. :contentReference[oaicite:5]{index=5}